Literature DB >> 11857350

Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.

Ulrike Stein1, Hermann Lage, Andreas Jordan, Wolfgang Walther, Susan E Bates, Thomas Litman, Peter Hohenberger, Manfred Dietel.   

Abstract

The impact of the ABC transporters breast cancer resistance protein/mitoxantrone resistance associated transporter (BCRP/MXR), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance gene-1/P-glycoprotein (MDR1/PGP) on the multidrug resistance (MDR) phenotype in chemoresistance and thermoresistance was investigated in the parental human gastric carcinoma cell line EPG85-257P, the atypical MDR subline EPG85-257RNOV, the classical MDR subline EPG85-257RDB and their thermoresistant counterparts EPG85-257P-TR, EPG85-257RNOV-TR and EPG85-257RDB-TR. Within the atypical MDR subline EPG85-257RNOV expression of BCRP/MXR and of MRP1 were clearly enhanced (vs. parental and classical MDR lines). MDR1/PGP expression was distinctly elevated in the classical MDR subline EPG85-257RDB (vs. parental and atypical MDR sublines). In all thermoresistant counterparts basal expression of BCRP/MXR, MRP1 and MDR1/PGP was increased relative to thermosensitive sublines. Although it could be shown that the overexpressed ABC transporters were functionally active, however, no decreased drug accumulations of doxorubicin, mitoxantrone and rhodamine 123 were observed. Thus, expression of BCRP/MXR, MRP1 and MDR1/PGP was found to be dependent on the appropriate type of chemoresistance; correlating with a classical or atypical MDR phenotype. Within the thermoresistant variants, however, the increase in ABC transporter expression did obviously not influence the MDR phenotype. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857350     DOI: 10.1002/ijc.10131

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

2.  Evaluation the interaction of ABC multidrug transporter MDR1 with thymoquinone: substrate or inhibitor?

Authors:  Vahideh Keyvani; Zeinab Nasserifar; Mohammad-Reza Saberi; Seyed Ahmad Mohajeri; Sepideh Arabzadeh; Farajollah Shahriari Ahmadi; Hossein Hosseinzadeh; Seyedeh Mahya Shariat Razavi; Fatemeh Kalalinia
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

3.  Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone.

Authors:  Da-Qiang Li; Zhi-Biao Wang; Jin Bai; Jie Zhao; Yuan Wang; Kai Hu; Yong-Hong Du
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

4.  DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.

Authors:  Jun Fang; Zhimin Ye; Feiying Gu; Maohui Yan; Qingren Lin; Juan Lin; Zhun Wang; Yaping Xu; Yuezhen Wang
Journal:  Oncol Lett       Date:  2018-05-29       Impact factor: 2.967

5.  A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.

Authors:  Rakesh K Singh; Thilo S Lange; Kyu Kwang Kim; Sunil K Shaw; Laurent Brard
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

6.  Kinetic Modeling of ABCG2 Transporter Heterogeneity: A Quantitative, Single-Cell Analysis of the Side Population Assay.

Authors:  Adam F Prasanphanich; Douglas E White; Margaret A Gran; Melissa L Kemp
Journal:  PLoS Comput Biol       Date:  2016-11-16       Impact factor: 4.475

Review 7.  Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies.

Authors:  Simona Pompili; Antonella Vetuschi; Roberta Sferra; Alfredo Cappariello
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

8.  TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

Authors:  Rosa S Schneiderman; Esther Shmueli; Eilon D Kirson; Yoram Palti
Journal:  BMC Cancer       Date:  2010-05-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.